LLY250110C820000
- 0.17
- +0.05+41.67%
Eli Lilly and Co Newsroom
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Medicare Can Cover Zepbound for Sleep Apnea, Creating a Significant Opportunity for Eli Lilly
Medicare Will Pay for Zepbound for Some Patients. The Costs Could Be Huge -- Barrons.com
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
LLY Falls Around 14% in 3 Months: How to Play the Stock
Express News | Eli Lilly - New Centre Expected to Open in Mid-2025
Express News | Lilly - to Establish New Global Capability Centre in Hyderabad, India
Eli Lilly and Co's Zepbound for the treatment of apnea can be included in the health insurance program.
On January 9, according to CNBC, the USA's Centers for Medicare and Medicaid Services reported that consumers can include Eli Lilly and Co's obesity drug Zepbound, used for treating sleep apnea, in their Medicare plans.
Medicare Expands Coverage of Eli Lilly's Weight-Loss Drug -- WSJ
Express News | CMS: With FDA Approved Use for Zepbound to Treat Obstructive Sleep Apnea, Current Medicare Part D and Medicaid Coverage Rules Apply
Express News | Consumers in the USA can include Eli Lilly and Co's Zepbound, purchased for the treatment of sleep apnea, under Medicare.
'Medicare Can Now Cover Eli Lilly's Zepbound For Sleep Apnea, CMS Says' - CNBC
Novo Nordisk Needs Answers to These 5 Key Questions
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,029
What Trump's Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk
These Stocks Are Expected to See at Least 25% Revenue Growth in 2025 – Wolfe
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not
Eli Lilly's Options: A Look at What the Big Money Is Thinking
Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says